Last edition
News about Drug Discovery & Development
Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study
Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.
Drug Discovery & Development | 30/03/2026 | By News Bureau | 213
PharmaJet, REDE-TB to Launch Clinical Study on Needle-Free TB Skin Testing Technology
The study will evaluate accuracy, safety and patient acceptance of needle-free Tropis system compared to traditional tuberculin skin test
Drug Discovery & Development | 26/03/2026 | By News Bureau | 129
LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia
LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.
Drug Discovery & Development | 26/03/2026 | By News Bureau | 226
Dupixent Approval in Japan Boosts Biologics Manufacturing Demand for Sanofi and Regeneron
The Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization to Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), a rare and debilitating skin disorder.
Drug Discovery & Development | 25/03/2026 | By Darshana | 170
Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer
Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.
Drug Discovery & Development | 19/03/2026 | By News Bureau | 159
US FDA Pushes Shift Away from Animal Testing in Early Drug Studies
The U.S. Food and Drug Administration (FDA) is pushing for a shift away from animal testing in early-stage drug development, encouraging companies to adopt more modern and human-relevant methods.
Drug Discovery & Development | 19/03/2026 | By Darshana | 155
A National Institutes of Health-backed study shows weekly injectable buprenorphine improves opioid abstinence and reduces serious risks compared to sublingual treatment in pregnant women with opioid use disorder.
Drug Discovery & Development | 18/03/2026 | By News Bureau | 161
Shanghai UniXell Biotechnology. has received US Food and Drug Administration IND clearance for UX-GIP001, marking the first iPSC-derived allogeneic cell therapy to enter clinical trials for Epilepsy in the US.
Drug Discovery & Development | 17/03/2026 | By News Bureau | 247
KORU Medical Gains EU MDR Approval For Freedom60 Infusion Pump
KORU Medical Systems has announced that its Freedom60 Infusion Pump, including the adapter designed for use with 50 mL prefilled syringes, has received certification under the European Union Medical Devices Regulation (EU MDR 2017/745). The certification allows the company to commercialise the device across the European Union.
Drug Discovery & Development | 16/03/2026 | By Darshana | 155
Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.
Drug Discovery & Development | 16/03/2026 | By News Bureau | 160
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy